Clinical trials: Primary Immune Thrombocytopenia (ITP)
Primary Immune Thrombocytopenia (ITP)
Immunomodulation With Eltrombopag in ITP
The study aims to investigate immunomodulatory effects of eltrombopag combined with dexamethasone in young and midlife adult patients with newly diagnosed primary Immune thrombocytopenia (ITP).
- Trial name
- iROM2 (NCT04812483)
- Testing
- Eltrombopag (Revolade®), standard therapy (without eltrombopag): HD-DXM
- Where
- 6 sites in Switzerland
- Volunteers
- 2 people
- Sponsor
- University Children's Hospital Basel
Primary Immune Thrombocytopenia (ITP)
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This multicenter randomized, open-label study aim to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or…
- Trial name
- NCT05718856
- Testing
- TPO-RAs, TPO-RAs combining anti-CD 20 monoclonal antibody
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Primary Immune Thrombocytopenia (ITP)
Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe
The goal of this multicenter, observational, retrospective is to evaluate the standards of use of thrombopoietin receptor agonists (TPO-RA) in adult patients with primary immune thrombocytopenia (ITP), with a particular interest…
- Trial name
- NCT06408324
- Where
- 17 sites in France, Italy and 4 more
- Volunteers
- 275 people
- Sponsor
- European Research Consortium on ITP
Chronic Primary Immune Thrombocytopenia (ITP)
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients with Chronic Primary Immune Thrombocytopenia
- Trial name
- NCT06004856
- Testing
- Orelabrutinib
- Where
- 45 sites in China
- Volunteers
- 195 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Primary Immune Thrombocytopenia (ITP)
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
Primary immune thrombocytopenia (ITP) is an autoimmune disease mainly mediated by autoreactive B cells and the presence of pathogenic anti-platelet auto-antibodies that enhance platelet destruction and impair platelet production.
- Trial name
- RITUX-PLUS 2 (NCT05338190)
- Testing
- Combination of Rituximab with subcutaneous belimumab
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Immune Thrombocytopenia (ITP)
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.
- Trial name
- ADVANCE2 (NCT04274452)
- Testing
- efgartigimod
- Sponsor
- argenx
Primary Immune Thrombocytopenia (ITP)
Study of Immune Thrombocytopenia Pathogenesis:
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells.
- Trial name
- PTI PARI (NCT02042560)
- Testing
- Blood samples, Spleen samples
- Where
- 3 sites in France
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon